RVTY Revvity, Inc. Common Stock

Revvity has been on fire lately. In the past six months alone, the company’s stock price has rocketed 78%, reaching $150.93 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

RVTY's diagnostics growth, AI-driven demand and life sciences expansion support its outlook, though China and margin pressures pose near-term challenges.

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

Revvity launches a CE-IVDR-certified automated T1D screening kit for children, expanding its GSP platform from newborn screening into early childhood.

Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index increasing 0.9

All three major US stock indexes fell in late-morning trading Thursday amid uncertainty in the Middl

Revvity has notably outperformed the Dow over the past year, and analysts are moderately optimistic about the stock’s prospects.

Revvity (RVTY) has drawn fresh attention after recent share price gains, with the stock up about 15% over the past month and roughly 36% over the past 3 months. Over the past year, Revvity has shifted from lagging long term returns, with a 5 year total shareholder return down 16.56%, to strong recent momentum. The 1 year total shareholder return reached 67.67%, and the 90 day share price return came in at 35.67%. Scan beyond Revvity's sharp rebound and explore other hand-picked opportunities...

The Standard & Poor's 500 index slipped 0.1% this week as the market digested a quarter-point rate i

Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.

Revvity (RVTY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the research tools & consumables industry, including Revvity (NYSE:RVTY) and its peers.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 30% gain over the past six months, beating the S&P 500 by 16.7 percentage points.

RVTY's HCD deal is expected to add human pancreatic beta cell models, expanding drug discovery and preclinical research tools for metabolic diseases.

Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but premium valuation and software risks call for selectivity.

Revvity has delivered a strong 57.5% return over the past year, while valuation checks send mixed signals. The Discounted Cash Flow (DCF) intrinsic value estimate suggests the stock is roughly in line with fair value, and market-based multiples point to a richer price. Revvity’s 57.5% 1 year return sets a high bar for new buyers, who now need the fundamentals to justify a much higher share price base. The key support for the current valuation can come from the company’s ability to convert...

Revvity (RVTY) is back in focus after a recent Zacks upgrade to Rank #2, which reflects improved earnings expectations even as questions remain about growth momentum and rising competitive pressure. Over the past year Revvity’s share price return has been strong, with a 30 day share price return of 12.5%, a 90 day share price return of 25.25% and a year to date share price return of 28.98%, while the 1 year total shareholder return is 44.46%. This suggests that positive momentum has been...

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.

Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Revvity's (RVTY) strong portfolio faces slowing growth and rising competition, raising questions abo

As UnitedHealth Group has outperformed relative to its industry peers over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Investors need to pay close attention to RVTY stock based on the movements in the options market lately.

Revvity has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

RVTY launches SuperFlex, a compact automated prenatal screening system aimed at expanding rapid in-house testing for smaller labs and clinics.

Revvity’s second quarter demonstrated year-over-year growth in both revenue and non-GAAP earnings, yet the market responded negatively, likely reflecting concerns about underlying segment dynamics and external factors. Management highlighted continued strength in its Diagnostics franchise, supported by robust organic growth and consistent performance in reproductive health and immunodiagnostics outside China. CEO Prahlad Singh pointed to "tangible signs of a more constructive spending environmen

Diagnostics surged 11% organically as AI-driven demand accelerated.

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.

Revvity (NYSE:RVTY) reported second-quarter results above its expectations and raised its full-year outlook, citing continued strength in diagnostics, improving demand from pharmaceutical and biotechnology customers, and growing orders tied to artificial intelligence-enabled drug discovery workflows

Revvity, Inc. reported past second-quarter 2026 results with sales of US$729.69 million, net income of US$51.82 million and diluted EPS from continuing operations of US$0.48, while also reaffirming a regular US$0.07 per-share quarterly dividend and issuing full-year 2026 revenue guidance of US$2.83 billion to US$2.86 billion. Management attributed the earnings beat and raised outlook to improving pharma and biotech spending, strong Diagnostics growth, especially in reproductive health and...

Moby summary of Revvity, Inc.'s Q2 2026 earnings call

Revvity beats Q2 earnings and sales estimates as Diagnostics growth, wider margins and strong cash flow support a higher 2026 outlook.

Revvity Inc (RVTY) beats expectations with 3% organic growth, raises full-year outlook on robust diagnostics performance and AI-driven demand.

Revvity, Inc. (NYSE:RVTY) reported second-quarter 2026 results that exceeded Wall Street expectations, prompting the health sciences company to raise its guidance for the full year.

Revvity (RVTY) delivered earnings and revenue surprises of +14.63% and +3.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Life sciences company Revvity (NYSE:RVTY) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 7.2% year on year to $729.7 million. The company’s full-year revenue guidance of $2.85 billion at the midpoint came in 0.5% above analysts’ estimates. Its non-GAAP profit of $1.41 per share was 15.9% above analysts’ consensus estimates.

Life sciences company Revvity (NYSE:RVTY) will be reporting earnings this Tuesday before the bell. Here’s what investors should know.

Organic revenue still fell, yet a segment returning to growth and a raised outlook were enough to reprice the stock in a single session.

RVTY heads into Q2 earnings with improving Life Sciences demand and resilient Diagnostics. Can stronger margins offset lingering headwinds?

CVS Health (CVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RVTY's T-SPOT A201 targets a 2027 launch, promising high-throughput latent TB testing with greater lab efficiency and scalability.

RVTY's Signals for Startups gives early-stage biotechs scalable software and guided onboarding to streamline research and support future growth.

If you’re an Alamar Biosciences (ALMR) shareholder, Friday was a good day. The stock climbed +7.3%, closing the session at a new 52-week high of $28.42. That’s a tidy gain on a day when the S&P 500 barely nudged up +0.4% and some key industry peers actually lost ground.